Transforming Gynecologic Cancer Treatment with Antibody-Drug Conjugates: Best Practices for Integrating Novel Therapies, Addressing Adverse Events, and Optimizing Multidisciplinary Collaboration

Friday, March 14, 2025

7:15 PM – 8:45 PM PT simulcast
8:15 PM – 9:45 PM MT
9:15 PM – 10:45 PM CT
10:15 PM – 11:45 PM ET

1.50 CME/CNE/ACPE Credits

Program Features:

  • Interactive case-based presentations and discussions
  • Online personalized quality-improvement poster-generation portal

Program Overview

Antibody-drug conjugates (ADCs) are an important advancement in the treatment of cancer. We are pleased to present an informative satellite symposium designed to equip you with information and skills needed to optimally use ADCs for your patients with advanced gynecologic cancers. This program will use an interactive format that includes didactic presentations, case presentations, and discussion sessions, along with audience response technology. Renowned experts will review the latest evidence and clinical guidelines related to ADCs for women’s cancers and share their perspectives and guidance on incorporating these agents into practice, including individualized treatment planning and multidisciplinary toxicity monitoring and management.

Learning Objectives

Upon the completion of this program, attendees should be able to:

  • Describe the mechanisms of action of antibody-drug conjugates (ADCs) and the rationale for their use in gynecologic cancers
  • Develop personalized strategies for incorporating ADCs into the treatment of patients with advanced gynecologic cancers
  • Assess and manage adverse events associated with administration of ADCs in gynecologic cancers

Target Audience

This activity is designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; advanced healthcare practitioners; nurses; and other healthcare professionals involved in the treatment of patients with gynecologic malignancies.

Joint Accreditation Statement

Joint Accreditation Statement

In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Credit Designation Statement

Med Learning Group designates this live activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

Nurses (ANCC) Credit Designation

Med Learning Group designates this activity for a maximum of 1.50 ANCC contact hours.

Pharmacists and Pharmacy Technicians (ACPE) Credit Designation

Med Learning Group designates this activity for a maximum of 1.50 knowledge-based CPE contact hours.

NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 45 days of your participation in the activity to meet the deadline for submission to CPE Monitor. Credits are generally reported during the first week of each month for those who claimed during the month prior.

Disclosure Policy Statement

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

Disclosure Of Unlabeled Use

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

Disclaimer

Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use. For CE questions, please contact Med Learning Group at info@medlearninggroup.com

Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at https://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

This activity is provided by Med Learning Group.
This activity is supported by educational grants from AbbVie Inc., Pfizer, and Genmab

Release date: March 14, 2025
Expiration date: March 14, 2025
Estimated time to completion: 1.5 hours